Schreiber, R., C. Lewis, and K. Crane. “Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance”. SKIN The Journal of Cutaneous Medicine, vol. 2, Dec. 2018, p. S57, doi:10.25251/skin.2.supp.57.